Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : The Microcap Kitchen: Stocks 5¢ to $5 -- Ignore unavailable to you. Want to Upgrade?

To: Catfish who wrote (16413)	1/5/2004 8:26:29 AM
From: CRUZ	Respond to of 120415

newsday.com Cruz

To: Catfish who wrote (16413)	1/5/2004 9:05:28 AM
From: Chris Forte	Respond to of 120415

OAK RIDGE, Tenn., Jan 5, 2004 (BUSINESS WIRE) -- Diversified Product Inspections, Inc. (OTCBB:DPRI), a provider of independent product failure analysis, air contamination and fire investigations for the insurance industry announced today, that monthly product liability inspections set a record in 2003. Warren Wankelman, Vice President of Marketing stated, "DPI processed over 9,350 inspections for the year 2003 resulting in a 20% increase over the inspection total of 7,765 for 2002. DPI's inspection volume has increased more than 200% since moving its operations from Florida to Oak Ridge, TN in 2000." Total Yearly Inspections Year Inspections 2000 3,082 2001 4,673 2002 7,765 2003 9,352 About Diversified Product Inspections, Inc. (www.dpi-inc.com) Launched in 1991 and headquartered in Oak Ridge, Tenn, Diversified Product Inspections, Inc. provides expertise and unbiased, independent investigations on product failures, air contamination and fire investigations of all multi-billion dollar markets which directly impact three groups--the insurance industry, manufacturers and consumers. In addition, DPI has developed an array of comprehensive services for these three targeted groups, giving the company the ability to better inform consumers of defective products and recalls (http://www.homechecksafety.com), improve quality control processes with manufacturers and work with the insurance industry to recover funds via subrogation -- a process whereby the insurer enforces its right to recoup from any third party that caused the loss on behalf of the policyholder. This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Act of 1995. The words "believe," "expect," "anticipate" and "project," and similar expressions identify forward-looking statements, which speak only as of the date the statement was made. Such statements may include, but not be limited to, projections of revenues, income or loss, expenses, plans, and assumptions relating to the foregoing. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Future results could differ materially from those described in forward-looking statements. SOURCE: Diversified Product Inspections, Inc. CONTACT: Diversified Product Inspections, Inc., Oak Ridge Matt Walters, 800-865-6220 Customize your Business Wire news & multimedia to match your needs. Get breaking news from companies and organizations worldwide. Logon for FREE today at www.BusinessWire.com. Copyright (C) 2004 Business Wire. All rights reserved. -0- KEYWORD: TENNESSEE FLORIDA INDUSTRY KEYWORD: LEGAL/LAW INSURANCE ENVIRONMENT MANUFACTURING * end of story *

To: Catfish who wrote (16413)	1/5/2004 9:08:59 AM
From: Catfish	Read Replies (1) \| Respond to of 120415

GNBT - Gapping up on this: Generex's Subsidiary Presents Promising Data on Efficacy of DNA Vaccine Technology at the NIH Conference Monday January 5, 9:01 am ET Therapy Cures Aggressive Cancer in Half of Mice Treated TORONTO, Jan. 5 /PRNewswire-FirstCall/ -- Generex Biotechnology Corporation (Nasdaq: GNBT - News), a leader in the area of buccal drug delivery, announced today that Antigen Express, Inc., its wholly-owned subsidiary, recently presented a poster on its DNA vaccine technology for cancer at the NIH Conference titled, "Innovative Administrative Systems for Vaccines." Robert Humphreys, M.D., Ph.D., Executive VP and Chief Scientific Officer of Antigen Express delivered the presentation in a poster that illustrated the benefits of using Antigen Express's proprietary and patented Ii protein antisense reagents to induce a T helper cell response to prostate cancer antigens. The therapy cured about half of the mice with an aggressive, poorly immunogenic cancer. ADVERTISEMENT The conference also highlighted several methods of mucosal vaccination. Generex's technology, with RapidMist administration of vaccines, was identified as potentially proving useful in therapies for autoimmune diseases such as multiple sclerosis or in the control of asthma. In such a scenario, doctors and patients could prefer use of RapidMist, the company's needle-free technology. About Generex Generex is engaged in the research and development of drug delivery systems and technology. To date, it has focused on developing a platform technology for the buccal delivery -- delivery to the oral cavity for absorption through the inner mouth mucosa -- of drugs that historically have been administered only by injection. Generex's buccal delivery technology has application to a large number of drugs. Generex acquired Antigen Express in August. 2003. The core platform technologies of Antigen Express comprise immunotherapeutics for the treatment of malignant, infectious, allergic, and autoimmune diseases. This release and oral statements made from time to time by Generex representatives concerning the same subject matter may contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These statements can be identified by introductory words such as "expects," "plans," "intends," "believes," "will," "estimates," "forecasts," "projects" or words of similar meaning, and by the fact that they do not relate strictly to historical or current facts. Forward-looking statements frequently are used in discussing potential product applications, potential collaborations, product development activities, clinical studies, regulatory submissions and approvals, and similar operating matters. Many factors may cause actual results to differ from forward-looking statements, including inaccurate assumptions and a broad variety of risks and uncertainties, some of which are known and others of which are not. Known risks and uncertainties include those identified from time to time in the reports filed by Generex with the Securities and Exchange Commission, which should be considered together with any forward-looking statement. No forward-looking statement is a guarantee of future results or events, and one should avoid placing undue reliance on such statements. Generex claims the protection of the safe harbor for forward-looking statements that is contained in the Private Securities Litigation Reform Act